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Summary The effect of a single dose of APD on hypercalcaemia has been studied in advanced breast cancer.
Twenty-five patients were rehydrated intravenously for 48h. Twenty-three remained hypercalcaemic and
received 5-15mg APD as a 2h infusion. Eighteen patients achieved normocalcaemia, 15 after a dose of
< 15mg. One patient died within 24h from rapidly advancing disease and 4 remained hypercalcaemic.
Urinary calcium excretion increased during rehydration as glomerular function improved and tubular
reabsorption of calcium fell. After APD, calcium excretion fell to normal in 22/24 patients reflecting
inhibition of bone resorption. Hydroxyproline excretion remained high. The effect of a single dose of APD on
hypercalcaemia lasted a median of 11 days (range 7-17). Transient fever occurred in 2 patients, but there were
no other side effects. The possibility of long-term control of osteolysis using a 2 weekly schedule of APD
administration is now being studied.
Hypercalcaemia is a common metabolic complication of
malignancy (Fisken et al., 1980) occurring in 10% of patients
with metastatic breast cancer (Coleman & Rubens, 1987).
Management consists of rehydration with saline to restore
glomerular function and use of drugs to inhibit osteoclastic
bone resorption. A variety of agents are available to achieve
this (Body, 1984) but there is no uniformly effective, well
tolerated treatment.
The bisphosphonates, which bind to hydroxyapatite and
inhibit osteoclast function, provide an alternative approach
to treatment. Three bisphosphonates have been studied in
hypercalcaemia (Jung, 1982; Sleeboom et al., 1983; Ralston
et al., 1985b; Percival et al., 1985b). All are poorly absorbed
from the gut and the intravenous route is preferred.
Disodium dihydrogen (1-hydroxyethylidene) bisphosphonate
(EHDP, Etidronate) appears the least effective and inhibits
bone mineralization. Dichloromethylene bisphosphonate
(C12 MDP) has considerably less effect on mineralization but
relatively high dosages are required to inhibit osteolysis.
3(amino-1,1-hydroxypropylidene) bisphosphonate (APD,
AHPrBP) will inhibit bone resorption at low dose with
minimal influence on mineralization (Reitsma et al., 1980).
The possibility of long-term control of osteolysis with bis-
phosphonates has been proposed (Elomoaa et al., 1983; Elte
et al., 1986) but for this to be tested information is needed
on the duration of action of a single dose. To achieve this,
we have performed a detailed prospective investigation of
APD in hypercalcaemia secondary to metastatic breast
cancer using a single dose of APD after intravenous
rehydration.
Patients and methods
Twenty-five women with advanced breast cancer aged 31-75
(median 51 years) presenting consecutively with hyper-
calcaemia were studied. A serum calcium (adjusted for
albumin) above 2.7mmol1-1 was necessary for inclusion.
Twenty-one patients had widespread lytic bone metastases
confirmed radiologically and 4 had minimal or no skeletal
involvement defined as fewer than 5 lesions detectable on
radionuclide bone scan and normal plain radiographs.
All patients were rehydrated with at least 31 of normal
(0.9%) saline i.v. daily for a minimum of 48 h. Those
remaining hypercalcaemic after 48 h rehydration were treated
with 3 amino-i,1-hydroxypropylidene bisphosphonate (APD,
Ciba-Geigy Ltd., Basel). Twenty-three patients received APD
as a 2h i.v. infusion in 500ml 0.9% saline. In 22 patients the
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dose of APD was 15mg. One patient, with mild asymp-
tomatic hypercalcaemia (serum calcium <2.8mmol 1-1)
received 5mg. No further treatment, apart from i.v. fluids,
was given for at least 48 h to allow time for the APD to act
and the effect of this single dose on serum and urine
biochemistry observed. If no improvement in hypercalcaemia
had occurred after 48-72h, a second dose of APD was
given. Further doses were given, if hypercalcaemia persisted,
on alternate days thereafter to a cumulative maximum of
120mg. of APD. Two to three litres a day of i.v. saline were
continued until normocalcaemia was achieved.
Specific anti-cancer treatment was discontinued during the
study except for 2 patients progressing on norethisterone
acetate in whom treatment was continued to avoid confusion
in the event of a possible withdrawal response. No patient
had had hypercalcaemia induced within 2 weeks of starting
endocrine therapy, an occasional cause of this disturbance
(Legha et al., 1981). Nine patients were receiving low-dose
corticosteroids (<10mg prednisolone or equivalent) as part
of specific endocrine therapy or as replacement therapy with
concomitant aminoglutethimide. Patients on steroids, non-
steroidal anti-inflammatory drugs and diuretics continued on
these drugs at the same dose. When clinically justifiable a
change in systemic therapy was delayed for up to 4 weeks to
observe the duration of response to APD. This was possible
in 8 patients.
Biochemical assessment was performed daily until
normocalcaemia achieved, and at convenient intervals
thereafter. All blood and urine samples were taken in the
morning, usually before breakfast. Dietary calcium was not
strictly controlled as intestinal absorption of calcium is
known to fall during hypercalcaemia (Coombes et al., 1976).
Foods containing collagen were avoided after 6p.m. until
urine collection to reduce the dietary influence of
hydroxyproline excretion. Serum and urine samples were
stored at -20°C and analysed in convenient batches. The
serum calcium was corretced for albumin concentration by
adding 0.018 x (34-albumin concentration) to the measured
value (Orrell, 1971).
Calcium, urea and electrolytes, creatinine, albumin,
phosphate and alkaline phosphatase were measured on a
standard autoanalyser. Urinary calcium excretion was
expressed as a molar ratio relative to creatinine excretion
and as CaE, derived from the molar ratio multiplied by the
serum creatinine concentration. Reference to the normal
relationship between serum calcium and CaE was based on
the calcium infusion data of Peacock (Peacock et al.,
1969). The tubular maximum reabsorption of phosphate
(TmPO4/GFR) was determined from urine and serum
measurements of phosphate and creatinine by the method of
Bijvoet et al., 1980.
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Hydroxyproline was measured using a modification (Grant
et al., 1984) of the method described by Cleary and Saunders
(1974) and expressed as a molar ratio to urinary creatinine.
Serum parathyroid hormone was measured by radio-
immunoassay. All patients had a radionuclide bone scan and
radiographs of abnormal areas were taken to confirm the
presence of bone metastases.
Symptoms of hypercalcaemia were recorded daily and
graded according to the WHO classification for reporting
toxicity (WHO, 1979). In this report only the principal
symptoms of nausea and vomiting, coma and confusion have
been analysed. Pain assessment and constipation were
confounded by analgesia and are considered unassessable.
Table I Study results
Patients studied 25
Response to rehydration alone 2
Patients receiving APD 23
Early death I
Evaluable patients 22
Patients achieving normocalcaemia 18
Effective APD dose 5mg 1
15mg 14
2xlSmg 3
Patients resistant to APD 4
Results
Figure 1 shows the fall in serum calcium during treatment.
The median serum calcium before rehydration was
3.14mmol 1 (range 2.74-4.53). Intravenous rehydration led
to only a minor improvement in serum calcium and 23
patients remained hypercalcaemic after rehydration with a
median serum calcium of 3.05mmol1- 1 (range 2.72-4.35)
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Figure 1 Serum calcium response to APD (day 0) after
rehydration (mean values +s.e.m.).
and received APD. The serum calcium increased during
rehdyration in 8/25 (32%).
Eighteen of 23 patients became normocalcaemic after
APD with a steady fall in serum calcium over 48-96h
(Figure 1). Fourteen patients responded to a dose of 15mg
and 1 to 5mg. In 7 patients additional doses of APD were
necessary. Three of these patients achieved normocalcaemia
after a second dose 15mg (TableI). One patient died within
24h of APD from septicaemia and rapidly progressive
lymphangitis carcinomatosa. In 4 patients, hypercalcaemia
appeared resistant to APD despite cumulative doses of 30,
80, 90 and 120mg of APD. Three of these non-responders
were also refractory to mithramycin, 2 of them dying from
persistent hypercalcaemia. Temporary control of hyper-
calcaemia in 2 of the non-responders was achieved with
cytotoxic chemotherapy. In 3 of these non-responders there
was evidence of a predominantly humoral cause for
hypercalcaemia; there was minimal radiological evidence of
osteolytic bone disease and both tubular reabsorption of
calcium and urinary phosphate loss were increased.
Urinary calcium excretion, shown as a molar ratio of
calcium to creatinine in Table II and as CaE in Figure 2,
rose during rehydration but then fell towards normal as
bone resorption was inhibited by APD. In 2 patients the
calcium excretion remained high (molar ratio >0.5)
indicating incomplete inhibition of bone resorption. One of
these patients remained hypercalcaemic despite a total
cumulative dose of 120 mg. APD and the other became
hypercalcaemic again 7 days after a single dose of 5 mg.
Unexpectedly, hydroxyproline excretion remained elevated
throughout the study (Figure 3). Figure 4 shows how CaE
and serum calcium related to each other during treatment in
comparison to the normal range for these indices. Before
rehydration this lay to the right of the normal range
indicative of increased renal tubular reabsorption of calcium.
Rehydration resulted in a fall in renal tubular reabsorption
and restoration of the relationship to normal which was
maintained while serum calcium fell.
Table II Biochemical assessment before and after rehydration, and after APD (mean values +s.e.m.)
Study day -2 oa 2 4 6 10 14
Serum
Calcium [mmol -1] 3.28 (0.10) 3.15 (0.09) 2.88 (0.09) 2.61 (0.08) 2.51 (0.07) 2.60 (0.09) 2.74 (0.08)
Creatinine [umol 11] 108 (14) 97 (16) 84 (13) 76 (10) 62 (6) 64 (8) 63 (8)
Phosphate [mmol 1'] 0.94 (0.06) 0.89 (0.07) 0.80 (0.07) 0.70 (0.04) 0.70 (0.05) 0.75 (0.09) 0.83 (0.12)
Magnesium [mmol 1-'] 0.69 (0.03) 0.61 (0.04) 0.59 (0.03) 0.61 (0.04) 0.58 (0.04) 0.59 (0.10)
Urine
TmPO4/GFRb [mmol I-'] 0.59 (0.06) 0.63 (0.05) 0.65 (0.06) 0.65 (0.07) 0.59 (0.08) 0.72 (0.11) 0.74 (0.10)
Calcium/creatinine ratio [mmolmol '] 1.06 (0.11) 2.11 (0.20) 1.41 (0.21) 0.43 (0.17) 0.68 (0.18) 0.71 (0.14) 1.17 (0.11)
Sodium excretionc [mmoll-1] 2.02 (0.69) 3.70 (0.55) 3.21 (0.52) 2.15 (0.55) 1.99 (0.42) 0.94 (0.23) 0.58 (0.22)
Symptoms
Scored 2.9 (0.3) 2.0 (0.4) 1.0 (0.3) 0.7 (0.3) 0.7 (0.3) 0.9 (0.3) 0.7 (0.3)
aAPD given on day 0; bTmPO4/GFR - tubular maximum reabsorption of phosphate; cSodium excretion =molar ratio of urinary sodium and
creatinine x serum creatinine; dSymptom score mean summation of WHO scores for nausea and vomiting, coma and confusion.APD FOR HYPERCALCAEMIA OF BREAST CANCER 467
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Figure 4 Relation between calcium excretion (CaE, ji mol 1 1
glomerular filtrate) and serum calcium. Points indicate mean
values +s.e.m. on day of study (APD given day 0).
TmCa/GFR= tubular maximum reabsorption of calcium.
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Figure 2 Calcium excretion index (CaE) during rehydration and
after APD (day 0). (mean values +s.e.m.). CaE=molar ratio of
urinary calcium to creatinine multiplied by serum creatinine.
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Figure 3 Urinary hydroxyproline excretion during treatment
(mean values +s.e.m.).
Table II summarises other biochemical data. Serum
creatinine fell slightly during rehydration as the glomerular
filtration rate (GFR) rose. The continued fall in serum
creatinine after adequate rehydration suggests that the GFR
did not return to normal until normocalcaemia was
achieved. The serum phosphate fell during rehydration as the
GFR rose, and was slow to return to normal as tubular
function recovered and TmPO4/GFR increased. Sodium
excretion (NaE) rose during rehydration as the salt deficit
was replaced and gradually fell as the diuretic effect of
excess calcium was removed and the i.v. saline reduced.
Serum magnesium levels remained low throughout the study.
Parathyroid hormone (PTH) was low or undetectable
(<400 ngml-1) in 22 patients. In 3 inconsistent, slight
elevation of PTH of uncertain significance was noted.
All patients presented with symptoms attributable to
hypercalcaemia. Subjective improvement invariably occurred
after rehydration despite minimal improvement in serum
calcium and continued until normocalcaemia was achieved
(Table II). Many patients complained of persisting lethargy
despite normocalcaemia. Although advanced malignancy
may have been the cause of this it seems probable that
persistent hypomagnasaemia contributed to this. In more
than half of the patients serum magnesium levels remained
below the normal range for 7 to 10 days after correction of
serum calcium.
APD was tolerated without significant toxicity. A transient
fever occurred in 2 patients. There was no gastro-intestinal
toxicity, lymphopenia, renal impairment or local thrombo-
phlebitis. The duration of action of APD was evaluable in 8
patients. Hypercalcaemia recurred 7-17 days after APD
administration (median 11 days). In the other 10 patients
achieving normocalcaemia additional systemic therapy,
usually for rapidly progressing liver metastases, was
necessary; hypercalcaemia recurred within 2 weeks in four.
Discussion
Hypercalcaemia is an unpleasant and life-threatening compli-
cation of malignancy. Although the patient's prognosis
may be poor, prompt effective treatment is necessary to
relieve symptoms before appropriate anti-tumour therapy
is started. The pathogenesis of hypercalcaemia is not
fully understood (Mundy, 1985). The relative contributions
of metastatic bone destruction (Ralston et al., 1984), renal
impairment, and humoral factor(s) remain contentious
(Percival et al., 1985a) and probably differ from patient
to patient. The tumour type influences the predominant
component and bone metastases are particularly common,
although not invariable, in patients with hypercalcaemia
secondary to breast cancer (Coleman & Rubens, 1987). The
4/25 (16%) incidence of hypercalcaemia without widespread
bone metastases observed here is similar to that recorded in
a recent retrospective review of hypercalcaemia (Coleman &
Rubens, 1987).
Intravenous rehydration is the essential immediate
treatment (Hosking et al., 1982). Calcium has a powerful
diuretic effect causing salt and water depletion. Urinary
excretion of calcium is impaired by several factors - the fall
in glomerular filtration, tubular damage secondary to the
hypercalcaemia and sometimes the secretion by the tumour
of a humoral factor with parathyroid hormone - like actions
on the kidney (Mundy et al., 1985).
Rehydration led to a small improvement in symptoms and
renal function. The mean serum calcium fell by
0.13 mmol l- 1, less than in other studies (Hosking et al.,
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1982; Percival et al., 1984), with a rise in calcium in 8
patients. Immobilization may have contributed to the
deterioration seen in these patients. Renal tubular
reabsorption of calcium also fell following rehydration,
resulting in a rise in urinary calcium excretion (Figure 2) and
restoration of the normal relationship between serum and
urinary calcium (Figure 4).
This study confirms the efficacy and lack of toxicity of
APD with return of serum calcium to normal in 18/22 (82%)
evaluable patients. A single 15mg infusion of APD was
effective in 15 patients. In these patients both serum and
urinary calcium levels fell after 24h, with a maximum effect
by 4-5 days. In the other 3 patients who responded to APD
an additional 15mg was given after 48 h. Urinary calcium
excretion had begun to fall in these patients and the second
dose may not have been necessary; improvement in serum
calcium followed over the next few days. The relatively slow
onset of action was not of clinical importance in controlling
hypercalcaemia in this study. A more rapid effect is possible
if necessary by combining calcitonin and APD due to the
direct effect of calcitonin on tubular function (Ralston et al.,
1986).
The four patients refractory to APD showed no significant
improvement in serum calcium despite repeated doses. Three
had a predominantly humoral mechanism responsible for
hypercalcaemia with no radiological evidence of lytic bone
disease, and five or fewer lesions on the bone scan. Urinary
calcium excretion fell to normal in 3, suggesting adequate
inhibition of bone resorption but the tubular effects of any
humoral factor could not be expected to respond to
APD. Relative resistance of humoral hypercalcaemia to
bisphosphonates has been observed previously (Ralston et al.,
1985a). No adequate explanation can be given for failure
of repeated doses (total 120mg) to control hypercalcaemia
in the remaining patient. This patient had extensive rapidly
progressing lytic bone disease and a direct effect of breast
cancer cells on bone resorption, late in the metastatic
process, may have been responsible (Galasko & Bennett,
1976).
The persistence of increased hydroxyproline excretion is at
variance with some previous studies (Sleeboom et al., 1983;
Ralston et al., 1985b). Diet and extra-skeletal disease may
have been significant additional sources of hydroxyproline.
Despite control of hypercalcaemia, incomplete hydroxy-
proline response has been observed (Percival et al., 1985b),
and the value of hydroxyproline as an index of bone
resorption in monitoring systemic therapy has been
inconsistent (Coombes et al., 1983).
Symptomatic response was rapid with both rehydration
and correction of serum calcium by APD contributing.
Hypomagnaesaemia results from tubular damage secondary
to hypercalcaemia. Restoration of serum magnaesium to
normal levels has been reported following APD (Sleeboom
et al., 1983) but did not occur in this study. Magnesium
replacement may be worthwhile to minimise the lethargy
induced by hypomagnaesaemia.
A reliable assay or label is not available to obtain
pharmacokinetic data on the bisphosphonates. Previous
reports have suggested a duration of action of several weeks
but this has been after multiple administrations (Kanis et al.,
1986) or confused by confounding factors (Cantwell &
Harris, 1987) including incomplete rehydration, concomitant
steroids and different tumour types. The duration of action
cannot oe stated with certainty from this study, but in a
small number of patients not requiring additional systemic
therapy hypercalcaemia recurred after 10-14 days. The
effects of larger doses of APD or prolonged (24h) infusions
were not addressed in this study but may differ from the 2h
infusion of 15 mg used here. The duration of control of
osteolysis may be influenced by both the dose (Thiebaud &
Jaeger, 1987) and infusion schedule of APD (Data on file,
Ciba-Geigy Ltd., Horsham).
APD is a useful, safe drug in the management of acute
tumour-induced hypercalcaemia. Control of recurrent hyper-
calcaemia with doses repeated fortnightly has been possible
in 3 patients (unpublished observations) although eventual
resistance developed after 2-3 months. The reversal and
long-term control of osteolysis with bisphosphonates to
decrease the morbidity from metastatic breast cancer is now
a definite possibility. Based on the data reported here we are
now testing a two weekly schedule of intravenous APD for
this purpose.
We wish to thank Mr G. Chik and Ms S. Hoare for their technical
assistance, the nursing staff for help with sample collection, and
Ciba-Geigy Ltd. for supplies of APD.
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